Drug addiction unveils a repressive methylation ceiling in EZH2-mutant lymphoma

Area of Science:

• Cancer Biology
• Epigenetics
• Molecular Oncology

Background:

• Cancer cells can develop a paradoxical dependence on continuous drug treatment for survival, a phenomenon termed "drug addiction."
• Understanding the underlying cell signaling mechanisms and cancer codependencies is crucial for developing novel therapeutic strategies.

Purpose of the Study:

• To identify mutations conferring drug addiction to polycomb repressive complex 2 (PRC2) inhibitors in diffuse large B-cell lymphoma.
• To elucidate the mechanisms by which these mutations mediate drug addiction and exploit resulting cancer vulnerabilities.

Main Methods:

• Identification and characterization of mutations in EZH2 associated with drug addiction.
• Analysis of H3K27me3 methylation patterns in response to PRC2 inhibition and drug withdrawal.
• Inhibition of SETD2 as a therapeutic strategy to exploit identified vulnerabilities.

Main Results:

• Hypermorphic mutations in the EZH2 CXC domain confer drug addiction by maintaining H3K27me3 levels despite PRC2 inhibitor treatment.
• Discontinuation of treatment leads to excessive H3K27me3 spread, exceeding a survival threshold for lymphoma cells.
• SETD2 inhibition effectively induces H3K27me3 spread and inhibits lymphoma growth, validating a therapeutic vulnerability.

Conclusions:

• Chromatin landscape constraints can lead to biphasic dependencies in cancer cell epigenetic signaling.
• Drug addiction mutations can be leveraged to discover novel cancer vulnerabilities and therapeutic targets in epigenetic regulation.